20th International AIDS Conference - Melbourne, Australia


TUWS11 Research to Measure Success of Antiretroviral (ARV) Use for Prevention and Treatment at Individual and Community Levels
  Scientific Development Workshop
Venue: Room 109-110
Time: 22.07.2014, 14:30 - 17:30
Co-Facilitators: Deborah Donnell, United States
Anton Pozniak, United Kingdom
Andrew Hill, United Kingdom
Francois Dabis, France
Meg Doherty, WHO

Level: Advanced
Target audience: General researcher, Clinical science, Epidemiologist
Seating limits: 400
This workshop will bring together experts in trial designs at both the individual and community level. It will be divided into two parts: designing and interpreting studies for success in terms of individual health; and designing and interpreting studies of ARV for prevention. HIV clinical trials tend to under-represent key patient groups seen in low-income countries. Trials of new treatments may be more difficult to conduct in low-income countries, where treatment options outside the trials are limited. Simple sequences of "Pill A to Pill B" ARV need to be evaluated in real-life settings. Participants will gain an understanding of the strengths and weaknesses of different approaches and will build skills in how to critically analyze the main study designs currently used to evaluate the impact of ARV policies and implementation on HIV prevention.
14:31
TUWS1101
Introduction
M. Doherty, WHO

14:35
TUWS1102
Powerpoint
Part 1: Designing and interpreting studies for success in terms of individual health
A. Pozniak, United Kingdom
A. Hill, United Kingdom

14:40
TUWS1103
Powerpoint
Is higher antiretroviral treatment coverage associated with lower HIV infection rates?
A. Hill, United Kingdom

14:55
TUWS1104
Can dose-optimization trials be conducted ethically in low-income countries?
A. Hill, United Kingdom

15:10
TUWS1105
Powerpoint
How can we evaluate simple sequences of first and second-line treatment in low-income countries?
A. Pozniak, United Kingdom

15:25
TUWS1106
Questions and answers

15:35
TUWS1107
Break

15:45
TUWS1108
Part 2: Designing and interpreting studies of ARVs for prevention
D. Donnell, United States
F. Dabis, France

15:50
TUWS1109
Powerpoint
Challenges in conducting Pre-Exposure Prophylaxis (PrEP) studies in low-income countries
D. Glidden, United States

16:05
TUWS1110
Powerpoint
Understanding temporal trends in HIV prevalence, incidence and ARV
V. Delpech, United Kingdom

16:20
TUWS1111
Powerpoint
Using demographic surveillance to combine ecological and geographical data with seroincidence
F. Tanser, South Africa

16:35
TUWS1112
Powerpoint
Choosing the primary endpoint for HIV prevention trials: example from the Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART) study
H. Ayles, Zambia

16:50
TUWS1113
Powerpoint
Ten years of achievements of the European and Developing Countries Clinical Trials Partnership (EDCTP), the European-African partnership for HIV clinical research: towards EDCTP-2
O. Olesen, Netherlands

17:05
TUWS1114
Questions and answers

17:20
TUWS1115
Conclusion
M. Doherty, WHO

Powerpoints presentations
Part 1: Designing and interpreting studies for success in terms of individual health -

Is higher antiretroviral treatment coverage associated with lower HIV infection rates? - Andrew Hill

How can we evaluate simple sequences of first and second-line treatment in low-income countries? - Anton Pozniak

Challenges in conducting Pre-Exposure Prophylaxis (PrEP) studies in low-income countries - David Glidden

Understanding temporal trends in HIV prevalence, incidence and ARV - Valerie Delpech

Using demographic surveillance to combine ecological and geographical data with seroincidence - Frank Tanser

Choosing the primary endpoint for HIV prevention trials: example from the Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART) study - Helen Ayles

Ten years of achievements of the European and Developing Countries Clinical Trials Partnership (EDCTP), the European-African partnership for HIV clinical research: towards EDCTP-2 - Ole Olesen



   

    The organizers reserve the right to amend the programme.